已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Imidazoline Receptor System: The Past, the Present, and the Future

咪唑啉受体 胍丁胺 莫索尼定 利门尼丁 可乐定 受体 兴奋剂 化学 药理学 立体化学 生物化学 内分泌学 医学 氨基酸 精氨酸
作者
Pascal Bousquet,Alan L. Hudson,Jesús A. Garcı́a-Sevilla,Jun‐Xu Li
出处
期刊:Pharmacological Reviews [American Society for Pharmacology and Experimental Therapeutics]
卷期号:72 (1): 50-79 被引量:88
标识
DOI:10.1124/pr.118.016311
摘要

Imidazoline receptors historically referred to a family of nonadrenergic binding sites that recognize compounds with an imidazoline moiety, although this has proven to be an oversimplification. For example, none of the proposed endogenous ligands for imidazoline receptors contain an imidazoline moiety but they are diverse in their chemical structure. Three receptor subtypes (I1, I2, and I3) have been proposed and the understanding of each has seen differing progress over the decades. I1 receptors partially mediate the central hypotensive effects of clonidine-like drugs. Moxonidine and rilmenidine have better therapeutic profiles (fewer side effects) than clonidine as antihypertensive drugs, thought to be due to their higher I1/α2-adrenoceptor selectivity. Newer I1 receptor agonists such as LNP599 [3-chloro-2-methyl-phenyl)-(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)-amine hydrochloride] have little to no activity on α2-adrenoceptors and demonstrate promising therapeutic potential for hypertension and metabolic syndrome. I2 receptors associate with several distinct proteins, but the identities of these proteins remain elusive. I2 receptor agonists have demonstrated various centrally mediated effects including antinociception and neuroprotection. A new I2 receptor agonist, CR4056 [2-phenyl-6-(1H-imidazol-1yl) quinazoline], demonstrated clear analgesic activity in a recently completed phase II clinical trial and holds great promise as a novel I2 receptor–based first-in-class nonopioid analgesic. The understanding of I3 receptors is relatively limited. Existing data suggest that I3 receptors may represent a binding site at the Kir6.2-subtype ATP-sensitive potassium channels in pancreatic β-cells and may be involved in insulin secretion. Despite the elusive nature of their molecular identities, recent progress on drug discovery targeting imidazoline receptors (I1 and I2) demonstrates the exciting potential of these compounds to elicit neuroprotection and to treat various disorders such as hypertension, metabolic syndrome, and chronic pain.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
甄的艾你完成签到,获得积分10
2秒前
2秒前
清新的音响完成签到 ,获得积分10
2秒前
彭于晏应助金枪鱼子采纳,获得100
2秒前
小鱼同学完成签到 ,获得积分10
3秒前
Worenxian完成签到,获得积分10
3秒前
飞飞飞fff完成签到 ,获得积分10
3秒前
小卒完成签到 ,获得积分10
5秒前
minnie完成签到 ,获得积分10
5秒前
chen完成签到 ,获得积分10
6秒前
7秒前
cdy完成签到,获得积分10
8秒前
fenghuo发布了新的文献求助10
8秒前
重要问丝完成签到 ,获得积分10
9秒前
小小飞xxf完成签到 ,获得积分10
10秒前
成就书雪完成签到,获得积分10
11秒前
哦哈哈完成签到 ,获得积分10
12秒前
宣灵薇完成签到 ,获得积分0
12秒前
tuanheqi发布了新的文献求助20
13秒前
Xiaoxiao应助星驰采纳,获得10
15秒前
威武大将军完成签到,获得积分10
16秒前
NS完成签到,获得积分10
16秒前
高源伯完成签到 ,获得积分10
17秒前
刘国建郭菱香完成签到 ,获得积分20
18秒前
阿俊完成签到 ,获得积分10
19秒前
沉默的觅海完成签到 ,获得积分10
19秒前
XCHI完成签到 ,获得积分10
19秒前
20秒前
亓杲杲完成签到,获得积分10
21秒前
LIFE2020完成签到 ,获得积分10
22秒前
1只白日梦完成签到 ,获得积分10
25秒前
Linda完成签到 ,获得积分10
27秒前
万事屋完成签到 ,获得积分10
28秒前
慕青应助光头狂采纳,获得10
28秒前
复杂棒球完成签到 ,获得积分10
28秒前
29秒前
风中琦完成签到 ,获得积分10
29秒前
29秒前
hanshishengye完成签到 ,获得积分10
33秒前
yys10l完成签到,获得积分10
34秒前
高分求助中
All the Birds of the World 4000
Production Logging: Theoretical and Interpretive Elements 3000
Animal Physiology 2000
Les Mantodea de Guyane Insecta, Polyneoptera 2000
Am Rande der Geschichte : mein Leben in China / Ruth Weiss 1500
CENTRAL BOOKS: A BRIEF HISTORY 1939 TO 1999 by Dave Cope 1000
Machine Learning Methods in Geoscience 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3739442
求助须知:如何正确求助?哪些是违规求助? 3282596
关于积分的说明 10030496
捐赠科研通 2999390
什么是DOI,文献DOI怎么找? 1645915
邀请新用户注册赠送积分活动 783003
科研通“疑难数据库(出版商)”最低求助积分说明 750205